Cargando…

5613043 THE EVOLUTION OF THE COVID-19 PANDEMIC IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE: FROM ALPHA TO OMICRON

Detalles Bibliográficos
Autores principales:	Martin, O.Y., Margulies, S., Speller-Brown, B., Majumdar, S., Darbari, D.S., Campbell, A.D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112567/ http://dx.doi.org/10.1097/01.HS9.0000928216.24317.52

Ejemplares similares

5613480 REAL WORLD APPLICATIONS OF CLINICAL WHOLE BLOOD ADHESION (VCAM AND P-SELECTIN) BIOMARKERS IN A PEDIATRIC SCD POPULATION
por: Martin, O.Y., et al.
Publicado: (2023)

Pediatric Sickle Cell Disease and the COVID-19 Pandemic: A Year in Review at Children's National Hospital
por: Martin, Olufunke Y., et al.
Publicado: (2021)

5616412 SOCIAL DETERMINANTS OF HEALTH AND THEIR IMPACT ON FAMILIES OF CHILDREN WITH SICKLE CELL DISEASE DURING COVID-19 PANDEMIC
por: Margulies, S.L.M., et al.
Publicado: (2023)

Clinical outcomes of children and adolescents with sickle cell disease and COVID-19 infection: A year in review at a metropolitan tertiary pediatric hospital
por: Martin, Olufunke Y., et al.
Publicado: (2023)

5613459 PAIN IN YOUTH WITH SICKLE CELL DISEASE AND ASSOCIATION WITH SLEEP
por: Hyppolite, R.H., et al.
Publicado: (2023)

Design of an adaptive randomized clinical trial of intravenous citrulline for sickle cell pain crisis in the emergency department
por: Majumdar, S., et al.
Publicado: (2023)

O-08: NEUROCOGNITIVE IMPAIRMENT IN UGANDAN CHILDREN WITH SICKLE CELL ANEMIA COMPARED TO NON-SICKLE SIBLINGS
por: P., BANGIRANA, et al.
Publicado: (2022)

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

5612992 SICKLE CELL HEALTH AWARENESS, PERSPECTIVES, AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND IMPACT ON THE QUALITY OF LIFE OF PATIENTS AND CAREGIVERS IN THE UK
por: Inusa, B.P.D., et al.
Publicado: (2023)

O-10: SICKLE CELL HEALTH AWARENESS, PERSPECTIVES AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND UNMET NEEDS AS REPORTED BY PATIENTS AND CAREGIVERS
por: I., ODAME, et al.
Publicado: (2022)

S110: ACUTE AND CHRONIC PAIN MANAGEMENT IN SICKLE CELL DISEASE: OUTCOMES OF AN ENGLISH NATIONAL AUDIT.
por: Lugthart, S, et al.
Publicado: (2022)

Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis
por: Zholobova, Elena, et al.
Publicado: (2014)

S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
por: Heeney, M, et al.
Publicado: (2022)

Mechanistic insights and characterization of cardiomyopathy due to Sickle Cell Disease
por: Patel, Amit R, et al.
Publicado: (2012)

S128: CONTINUOUS QUALITY IMPROVEMENT IN PAEDIATRIC SICKLE CELL DISEASE
por: Ahemad, E, et al.
Publicado: (2022)

S127: CONSORTIUM ON NEWBORN SCREENING IN AFRICA FOR SICKLE CELL DISEASE
por: Nnodu, O, et al.
Publicado: (2022)

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Osunkwo, I, et al.
Publicado: (2022)

5613081 GAPS IN DATA ON GLOBAL PREVALENCE AND BIRTH PREVALENCE OF SICKLE CELL DISEASE AND SICKLE CELL TRAIT: CALL FOR ACTION TO SCALE UP AND HARMONIZE DATA COLLECTION
por: Colombatti, R., et al.
Publicado: (2023)

S113: COST OF ILLNESS, EPIDEMIOLOGY AND HEALTHCARE RESOURCE UTILIZATION FOR SICKLE CELL DISEASE IN GULF COUNTRIES (CESCGU)
por: Alkindi, S, et al.
Publicado: (2022)

Genotypic, genetic and molecular characteristics of erythromycin C resistant Streptococcus pneumoniae from pediatric patients in Beijing, 2010
por: Zhou, L., et al.
Publicado: (2012)

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

P-065: IMPACT OF SOCIOECONOMIC FACTORS ON COGNITIVE FUNCTION IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE
por: A., DARBARI, et al.
Publicado: (2022)

S125: THE ROLE OF THE MICROBIOME AS A SICKLE CELL DISEASE MODIFIER: AN EXPERT REVIEW
por: Oosterwyk, C, et al.
Publicado: (2022)

5607610 HETEROGENEITY IN COGNITIVE PRESENTATIONS AMONG CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE
por: Hardy, S.J., et al.
Publicado: (2023)

5613275 USE OF CONSUMER WEARABLES TO PREDICT PAIN IN PATIENTS WITH SICKLE CELL DISEASE
por: Vuong, C., et al.
Publicado: (2023)

5613022 SOCIETAL BURDEN OF SICKLE CELL DISEASE IN THE UK: EMPIRICAL ESTIMATES OF PRODUCTIVITY LOSS AND LOSS OF FUTURE INCOME USING REAL-WORLD EVIDENCE
por: Besser, M., et al.
Publicado: (2023)

5612617 EFFICACY AND SAFETY OF A SINGLE DOSE OF EXAGAMGLOGENE AUTOTEMCEL FOR TRANSFUSION-DEPENDENT-THALASSEMIA AND SEVERE SICKLE CELL DISEASE
por: de la Fuente, J., et al.
Publicado: (2023)

S129: IMPLEMENTATION OF HYDROXYUREA THERAPY FOR SICKLE CELL DISEASE ON A LARGE SCALE IN GHANA
por: Ohene-Frempong, K, et al.
Publicado: (2022)

5595849 THE GUT MICROBIOME AND HYDROXYUREA EFFECT ON SICKLE CELL DISEASE CHILDREN FROM ANGOLA
por: Brito, M., et al.
Publicado: (2023)

5610692 PAIN BURDEN PREDICTS EXECUTIVE FUNCTION IN PAEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Chen, Y., et al.
Publicado: (2023)

O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
por: M., TELEN, et al.
Publicado: (2022)

O-11: AUTOMATED QUANTIFICATION OF POCKED RED BLOOD CELLS CORRELATES WITH SPLEEN SIZE IN SICKLE CELL DISEASE
por: A., SISSOKO, et al.
Publicado: (2022)

S118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL
por: Achebe, M, et al.
Publicado: (2022)

MR-Augmented Cardiopulmonary Exercise Testing- a proof of concept in Sickle Cell Disease (SCD)
por: Ako, Emmanuel O, et al.
Publicado: (2016)

S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

S130: PROCESSING SPEED DECLINES OVER TIME IN 4--25-YEAR-OLDS WITH SICKLE CELL DISEASE
por: Walker, E, et al.
Publicado: (2022)

O-07: TRANSFUSION PRACTICE, POST-TRANSFUSION COMPLICATIONS AND RISK FACTORS IN SICKLE CELL DISEASE IN SENEGAL
por: M., SECK, et al.
Publicado: (2022)

5612627 MORTALITY, CHRONIC MORBIDITY AND INTENSITY OF TREATMENTS IN A NATURAL HISTORY COHORT OF SICKLE CELL DISEASE
por: Reggiani, G., et al.
Publicado: (2023)

The impact of endoplasmic reticulum stress on neutrophil function in alpha 1 antitrypsin deficiency
por: Shaharom, M, et al.
Publicado: (2015)

O-13: INHIBITION OF THE ENDOCANNABINOID REGULATING ENZYME MONOACYLGLYCEROL LIPASE AMELIORATES THE HYPER-NOCICEPTIVE PHENOTYPE IN THE BERKELEY MOUSE MODEL OF SICKLE CELL DISEASE
por: K., GOLDSBOROUGH, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0pcc4ugluvis976v9p9g89pa3t